Eli Lilly took its first major enforcement step against the “black market” for retatrutide by filing lawsuits targeting six U.S. companies, alleging they sold unauthorized versions of the company’s investigational triple-G weight-loss drug. The complaints name compounding pharmacies, cosmetic/med spa operators, and online sellers that allegedly marketed products for human use while citing “research-use only” labels. Lilly said it has reported more than 200 entities to U.S. authorities including the FDA and the Department of Justice and documented 14,000-plus websites, ads, and listings promoting retatrutide copycats across more than 100 countries. The FDA has also issued buyer-and-seller warnings that compounded GLP-1 and related products carry unknown quality and potential health risks. The case raises the near-term compliance stakes for the pre-approval weight-loss ecosystem, where demand has outpaced regulated supply. It also highlights ongoing enforcement pressure on “off-label” and “compounded” claims that may obscure intended consumer use.